- IDEXX Laboratories reported fourth-quarter earnings per share (EPS) of $2.62, surpassing the previous year’s $2.32 and exceeding the estimate of $2.41.
- The company achieved revenue of $954.3 million, marking a 5.8% increase year-over-year, and beating the expected $935 million.
- Companion Animal Group (CAG) revenue rose by 6% to $870.5 million, surpassing the forecasted $853.5 million.
- Water segment revenue increased by 8.1% to $45.2 million, aligning with the estimates.
- Livestock, Poultry, and Dairy (LPD) revenue grew by 5.4% to $34.6 million, higher than the expected $32 million.
- Other revenue decreased by 29% to $4.11 million, falling short of the estimated $5.42 million.
- The gross margin improved to 59.8% from 58.4% last year, slightly better than the estimate of 59.7%.
- Operating income increased by 6.7% to $261.7 million, surpassing the estimated $256.7 million.
- IDEXX forecasts 2025 EPS between $11.74 and $12.24, anticipating a 10% to 15% increase as reported and 8% to 12% on a comparable basis.
- The 2025 revenue guidance is set between $4.06 billion and $4.17 billion, with expectations of 4% to 7% growth as reported and 6% to 9% growth organically.
- The operating margin for 2025 is projected to be between 31% and 31.5%, benefiting from a reduction in discretionary expenses.
- CAG Diagnostics recurring revenue is expected to grow between 3% and 6% reported, and 5% to 8% organically in 2025.
- Jay Mazelsky, President and CEO, attributed the strong 2024 finish to the global teams’ high level of execution.
- Analyst ratings include 8 buys, 6 holds, and 1 sell.
“`
IDEXX Laboratories on Smartkarma
Independent analysts on Smartkarma are providing insightful coverage of IDEXX Laboratories, a key player in diagnostics and veterinary healthcare. MBI Deep Dives released a bullish report titled “IDEXX: Leading the Humanization of Pet Care Through Diagnostics.” The report highlights society’s increasing humanization of pets and the emotional bond between pet parents and their furry companions.
Another bullish report by Baptista Research titled “IDEXX Labs: Will Its Enhanced Diagnostic Capabilities & Innovation Bring A Shift In The Competitive Dynamics?” analyzes IDEXX’s latest earnings report, showcasing a 6% organic revenue growth driven by Companion Animal Group Diagnostic recurring revenues. The report underscores both the strengths and challenges faced by IDEXX, offering valuable insights for prospective investors.
A look at IDEXX Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores analysis, IDEXX Laboratories has a promising long-term outlook. With high scores in growth, resilience, and momentum, the company appears well-positioned to capture future opportunities in the veterinary diagnostics and information systems sector. The strong growth score suggests that IDEXX may continue expanding its market presence and profitability over time. Additionally, its solid resilience and momentum scores indicate a stable performance and positive market sentiment, reflecting investor confidence in the company’s prospects.
Despite lower scores in value and dividend factors, IDEXX’s overall outlook seems positive, driven by its core strengths in growth, resilience, and momentum. As a provider of diagnostic solutions for veterinary, food, and water testing applications, IDEXX Laboratories maintains an international network of veterinary reference laboratories, catering to customers globally. This diversified business model positions IDEXX well for sustained growth and innovation in the evolving healthcare and diagnostics industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
